Drug intelligence / Profile preview

ganetespib + paclitaxel + trastuzumab

Development stage: Unknown
Lead developer: Madrigal Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination therapy consisting of three drugs—ganetespib (a heat shock protein 90 inhibitor), paclitaxel (a taxane chemotherapy agent), and trastuzumab (a monoclonal antibody targeting HER2). The combination has been investigated in clinical trials for the treatment of HER2-positive cancers, particularly metastatic breast cancer. Ganetespib inhibits HSP90, disrupting oncogenic client proteins; paclitaxel stabilizes microtubules to inhibit cell division; and trastuzumab binds to HER2 receptors to block signaling pathways that promote cancer cell growth[1][2].

Other names: ganetespib/paclitaxel/trastuzumabganetespib, paclitaxel, and trastuzumab

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))HSP90 (Heat shock protein 90 chaperone complex)

Beyond the preview

Go deeper on ganetespib + paclitaxel + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganetespib + paclitaxel + trastuzumab.

Explore the full profile